决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Components, Formulations, Deliveries, and Combinations of Tumor Vaccines.
肿瘤疫苗是免疫治疗的重要组成部分,通过激活或恢复机体自身的免疫系统来预防癌症或杀伤已有的肿瘤细胞。
肿瘤疫苗是免疫治疗的重要组成部分,可通过激活或恢复机体免疫系统预防癌症或杀伤现有肿瘤细胞。目前已有多种形式,包括细胞疫苗、肿瘤细胞膜疫苗、DNA疫苗、mRNA疫苗、多肽疫苗、病毒载体疫苗和肿瘤原位疫苗;递送系统则包括脂质体、细胞膜囊泡、病毒、外泌体和乳剂。为降低单一疫苗可能导致的免疫逃逸或耐受风险,将疫苗与放疗、化疗、免疫检查点抑制剂、细胞因子、CAR-T或光免疫疗法联合是一种有效策略。本文回顾肿瘤疫苗发展历史,并讨论抗原、佐剂、制剂、递送系统、作用机制、联合疗法及未来方向。
Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor cells by activating or restoring the body's own immune system. Currently, various formulations of tumor vaccines have been developed, including cell vaccines, tumor cell membrane vaccines, tumor DNA vaccines, tumor mRNA vaccines, tumor polypeptide vaccines, virus-vectored tumor vaccines, and tumor-in-situ vaccines. There are also multiple delivery systems for tumor vaccines, such as liposomes, cell membrane vesicles, viruses, exosomes, and emulsions. In addition, to decrease the risk of tumor immune escape and immune tolerance that may exist with a single tumor vaccine, combination therapy of tumor vaccines with radiotherapy, chemotherapy, immune checkpoint inhibitors, cytokines, CAR-T therapy, or photoimmunotherapy is an effective strategy. Given the critical role of tumor vaccines in immunotherapy, here, we look back to the history of tumor vaccines, and we discuss the antigens, adjuvants, formulations, delivery systems, mechanisms, combination therapy, and future directions of tumor vaccines.
MEMBER ACCOUNT
登录成功会直接打开下一页。